Monotherapy for partial epilepsy: focus on levetiracetam by Gambardella, Antonio et al.
© 2008 Dove Medical Press Limited.   All rights reserved
Neuropsychiatric Disease and Treatment 2008:4(1) 33–38
EXPERT OPINION
33
Monotherapy for partial epilepsy: focus 
on levetiracetam
Antonio Gambardella1,2
Angelo Labate1,2
Eleonora Colosimo1
Roberta Ambrosio1
Aldo Quattrone1,2
1Institute of Neurology, University 
Magna Græcia, Catanzaro, Italy; 
2Institute of Neurological Sciences, 
National Research Council, Piano 
Lago di Mangone, Cosenza, Italy
Correspondence: Antonio Gambardella
Cattedra ed U.O. di Neurologia, 
Università degli Studi “Magna Graecia”, 
Campus Universitario di Germaneto, Viale 
Europa, 88100 Catanzaro, Italy
Tel +39 0961 3647270
Fax +39 0961 3647177
Email a.gambardella@isn.cnr.it
Abstract: Levetiracetam (LEV), the S-enantiomer of alpha-ethyl-2-oxo-1-pyrollidine 
acetamide, is a recently licensed antiepileptic drug (AED) for adjunctive therapy of partial 
seizures. Its mechanism of action is uncertain but it exhibits a unique proﬁ  le of anticonvulsant 
activity in models of chronic epilepsy. Five randomized, double-blind, placebo-controlled 
trials enrolling adult or pediatric patients with refractory partial epilepsy have demonstrated 
the efﬁ  cacy of LEV as adjunctive therapy, with a responder rate ( 50% reduction in seizure 
frequency) of 28%–45%. Long-term efﬁ  cacy studies suggest retention rates of 60% after one 
year, with 13% of patients seizure-free for 6 months of the study and 8% seizure-free for 
1 year. More recent studies illustrated successful conversion to monotherapy in patients with 
refractory epilepsy, and its effectiveness as a single agent in partial epilepsy. LEV has also 
efﬁ  cacy in generalized epilepsies. Adverse effects of LEV, including somnolence, lethargy, and 
dizziness, are generally mild and their occurrence rate seems to be not signiﬁ  cantly different 
from that observed in placebo groups. LEV also has no clinically signiﬁ  cant pharmacokinetic 
interactions with other AEDs, or with commonly prescribed medications. The combination of 
effective antiepileptic properties with a relatively mild adverse effect proﬁ  le makes LEV an 
attractive therapy for partial seizures.
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Introduction
Levetiracetam (LEV), (S)-α-ethyl-2-oxo-pyrrolidine acetamide analog of piracetam 
(Shorvon 2001), is a new anticonvulsant agent with a favorable tolerability proﬁ  le 
and a low potential for drug interactions (Dooley and Plosker 2000). LEV was syn-
thesized in the early 1980s during a follow-up chemical program aimed at identify-
ing a second-generation nootropic drug, and initial pharmacologic studies with LEV 
explored its ability to facilitate cholinergic neurotransmission (Klitgaard 2001). In 
1991, pivotal clinical studies were initiated in epilepsy patients as adjunctive therapy 
in refractory partial onset seizures. In November 1999, the FDA approved LEV as a 
new antiepileptic drug (AED).
LEV has demonstrated efﬁ  cacy and a favorable tolerability proﬁ  le as adjunctive 
for partial seizures in adult and pediatric patients (Hovinga 2001; Shorvon and van 
Rijckevorsel). Moreover, there has been increasing evidence that LEV may also be 
useful in patients with generalized absence or myoclonic seizures, and in patients 
with Lennox-Gastaut syndrome (Kasteleijn-Nolst et al 1996; Labate et al 2006). 
LEV has become one of the most frequently prescribed new drugs for the treatment 
of partial seizures. It offers several advantages over traditional therapy, including 
twice daily dosing, a wide margin of safety with no requirements for serum drug 
concentration monitoring, and no interactions with other anticonvulsants. In addi-
tion, LEV appears to be well tolerated by most patients and may have less adverse 
effects on cognitive function than traditional agents (Dooley and Plosker 2000). Neuropsychiatric Disease and Treatment 2008:4(1) 34
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This advantageous pharmacologic profile makes LEV 
an attractive ﬁ  rst line or adjunctive therapy for epileptic 
seizures. This review focuses on the experience and use of 
LEV in partial epilepsy.
Experimental studies
The mechanism for the anticonvulsant effect of LEV still 
remains elusive. LEV is not chemically related to other anti-
convulsants and its mechanism of action seems to be unre-
lated to known mechanisms of neurotransmission. Indeed, 
unlike other AEDs, LEV has no effect in the two classic 
rodent models for AEDs, the maximal electroshock seizure 
and the pentylenetetrazol (Gower et al 1992; Löscher and 
Hönack 1993). Moreover, the drug does not bind to receptors 
associated with excitatory or inhibitory neurotransmitters 
including γ-aminobutyric acid (GABA), glutamate, glycine, 
adenosine; it also has no effect on sodium or T-type calcium 
channel function, and does not affect GABA transaminase 
or glutamic acid decarboxylase (GAD) activity or second 
messenger systems (cyclic adenosine monophosphate) or 
protein kinase C (Löscher and Hönack 1993). Conversely, 
LEV seems to partially inhibit N-type high-voltage–activated 
Ca2+ currents and reduces the Ca2+ release from intraneuronal 
stores (Gower et al 1995; Klitgaard et al 1998; Löscher et al 
1998; Rigo et al 2000; Niezpodziany et al 2001; Zona et al 
2001). It also reverses inhibition of GABA and glycine gated 
currents induced by negative allosteric modulators (Rigo et al 
2000), and effects voltage gated potassium channel conduc-
tance (Madeja et al 2001). LEV also has a speciﬁ  c stereose-
lective binding site in the CNS at the synaptic vesicle protein 
2A (SV2A) (Dooley and Plosker 2000; Rigo et al 2000), and 
cannot be displaced from this site by other classic AEDs such 
as carbamazepine, phenytoin, valproate, and phenobarbital, 
although ethosuximide does show binding afﬁ  nity. LEV has 
no binding to membranes outside of the CNS.
LEV has very marked protection against seizures in 
audiogenic mice, mice kindled with corneal electroshock 
or PTZ, and amygdaloid kindled rats (Klitgaard et al 1998; 
Löscher et al 1998). It protects against spontaneous spike 
and wave discharges in the GAERS model and in pilocarpine 
or kainic acid induced focal seizures in rats (Klitgaard et al 
1998; Löscher et al 1998). The extent of the antiepileptic 
efﬁ  cacy in the audiogenic seizure model in mice was found 
to be correlated with the afﬁ  nity for the binding site of a 
series of S-homologues of LEV (Noyer et al 1995). The 
dose-dependent ability of LEV to inhibit the development of 
kindling suggests a potential antiepileptogenic effect as well 
(Löscher et al 1998). LEV is the most effective of any of the 
pyrrolidone drugs in these epilepsy models. Its R-enantiomer 
has no antiepileptic activity.
The dose at which toxic effects on the rotarod test are 
produced is much higher than the effective antiseizure dose in 
both the GAERS model and the corneally kindled mice. The 
safety margin of LEV in these models is much greater than 
for other drugs (Harden 2001). In acute and chronic toxicity 
studies in animals, LEV shows generally low toxicity. Oral 
doses up to 5000 mg/kg acutely (maximum tested dose) 
are not lethal in mice and rats. LEV has not displayed any 
teratogenic, mutagenic, or carcinogenic properties (French 
et al 2001; Harden 2001).
Clinical pharmacokinetics
The pharmacokinetic properties of LEV have been studied 
in healthy adult volunteers, patients with epilepsy, and 
special populations, including pediatric and elderly patients 
and patients with renal or hepatic insufﬁ  ciency (Pellock 
et al 2001; Radtke 2001). LEV is highly soluble in water. 
It is formulated for clinical use as 250-, 500-, and 1000-mg 
ﬁ  lm-coated tablets. LEV is rapidly and almost completely 
absorbed after oral administration of doses ranging from 
250 mg to 5000 mg, with peak serum concentrations 
occurring approximately 1 hour after a dose and steady state 
concentrations reached within 48 hours. Absorption of LEV 
is unaffected by the presence of food or antacids, although the 
rate of absorption may be slowed. It has been now produced 
an IV formulation of LEV whose infusion is bioequivalent to 
oral tablets and is well tolerated after 15 min and 5 min IV 
infusion in healthy subjects (Ramael et al 2006).
LEV exhibits minimal protein binding ( 10%) and has a 
volume of distribution of 0.5–0.7 L/kg in adults, similar to the 
volume of distribution of intracellular and extracellular water. 
In addition, LEV exhibits linear, dose proportional, kinetics, 
with low intrasubject and intersubject variability, and a half-
life of 6–8 hours (Pellock et al 2001; Radtke 2001).
LEV is eliminated through renal excretion, primarily 
as unchanged drug. LEV does not undergo hepatic 
metabolism (Nicolas et al 1999), even if a minor percentage 
undergoes hepatic metabolism via enzymatic hydrolysis and 
hydroxylation to inactive byproducts. Clearance is rapid, 
so that within 48 hours approximately 93% of an oral dose 
is eliminated. The elimination half-life of LEV in healthy 
adults ranges from 6 to 8 hours, in children is 5–7 hours and 
in elderly between 10 and 11 hours, regardless of dosage 
or frequency of administration. The prolonged elimination 
half life of LEV in the elderly is likely attributable to the 
age related decline in renal function. Average total body Neuropsychiatric Disease and Treatment 2008:4(1)
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clearance is 0.96 mL/min/kg in adults, with a renal clearance 
of 0.6 ml/min/kg. After single oral dose administration of 
20 mg/kg LEV in children between 6 and 12 years of age, total 
body clearance was about 30%–40% higher than in adults. 
Renal clearance of LEV is directly proportional to creatinine 
clearance. In adult patients with severe renal impairment 
(creatinine clearance  30 mL/min), LEV clearance is 
reduced by approximately 60% (Radtke 2001). Clearance of 
LEV is signiﬁ  cantly reduced in patients with severe hepatic 
impairment and concomitant renal impairment (hepatorenal 
syndrome). No differences are seen in patients with mild to 
moderate hepatic impairment (Pellock et al 2001).
The recommended dosing regimen for LEV as add on 
therapy is twice daily doses of 500–1500 mg, for a total 
daily dosage of between 1000 mg and 3000 mg. Higher 
doses have been studied, but with little evidence of added 
effectiveness. The initial starting dose of 1000 mg/day 
has been shown to be clinically effective, but if sufﬁ  cient 
seizure control is not obtained, doses can be increased up 
to 3000 mg/day. LEV has been shown to be effective as 
early as the ﬁ  rst day of therapy, and this rapid effect is 
complemented by a sustained efﬁ  cacy (French and Arrigo 
2005). In patients with renal impairment, doses should be 
reduced in accordance with creatinine clearance (Keppra 
2000a, b). Presently, there are no sufﬁ  cient data to recom-
mend treatment with LEV during pregnancy. In patients 
withdrawn from LEV, a gradual tapering of 1000 mg every 
1–2 weeks has been successful and has not resulted in 
withdrawal seizures.
Drug interactions
Because of its advantageous pharmacokinetic, LEV does 
not appear to interact with other AEDs (Nicolas et al 1999), 
and the overall pharmacokinetic parameters of LEV during 
polytherapy with AEDs are comparable to those of subjects 
receiving LEV alone. The pharmacokinetic proﬁ  le of LEV is 
not inﬂ  uenced by phenytoin, phenobarbital, primidone, car-
bamazepine, valproic acid, lamotrigine, gabapentin, digoxin, 
oral contraceptives ethinylestradiol, and warfarin (Browne 
et al 2000; French et al 2001; Levy et al 2001; Radtke 2001; 
Shorvon and van Rijckevorsel 2002). Similarly, the addition 
of LEV does not signiﬁ  cantly alter serum concentrations of 
all these drugs. Pooled analysis conﬁ  rmed these ﬁ  ndings 
(Gidal et al 2005). The possible interaction between LEV and 
tiagabine, topiramate, and zonisamide has not been investi-
gated. A recent experimental study illustrated a pharmaco-
kinetic contribution other than pharmacodynamic interaction 
between LEV and felbamate (Luszczki et al 2007).
Side effects
The most commonly reported adverse effects during clinical 
trials with LEV in adults were primarily related to the CNS 
and included somnolence (15% of patients), asthenia (15%), 
headache (14%), infection (13%), dizziness (9%), and ataxia 
(3%) (Ben-Menachem and Falter 2000; Cereghino et al 2000; 
Shorvon et al 2000). These adverse effects were seen most 
frequently in the ﬁ  rst month of therapy and typically lessened 
or resolved with continued treatment. In the pooled analysis, 
there was no evidence of a dose dependent relation within 
the recommended dose range of 1000–3000 mg/day (Gidal 
et al 2005). Patients receiving LEV also reported a slightly 
higher incidence of symptoms of upper respiratory infection, 
which was not associated with leucopenia or dose reduction. 
In clinical trials, from one to 4% of patients have withdrawn 
because of these effects (Ben-Menachem and Falter 2000; 
Cereghino et al 2000; Shorvon et al 2000; Tsai et al 2006). 
Similar adverse effects, but higher percentages, were reported 
in pediatric populations (Glauser et al 2002, 2006).
In pre-marketing studies of LEV, up to 13% of patients 
have experienced adverse neuropsychiatric symptoms. 
In most of these patients, the symptoms have been mild, 
including agitation, hostility, apathy, anxiety, emotional 
lability, and depression. Nonetheless, about 1% of pediatric 
or adult patients have experienced serious neuropsychiatric 
symptoms including hallucinations, suicidal ideations, or 
psychosis, after beginning LEV (Kossoff et al 2001; Mula 
et al 2003). There was a signiﬁ  cant association between 
psychiatric adverse events and previous history of febrile 
convulsions or status epilepticus, while a past personal or 
family history of psychiatric disorders was more important 
in predicting the features of psychiatric adverse events rather 
than their occurrence. Moreover, psychiatric adverse events 
were not related to the starting dose, titration schedule of LEV 
or the rate of seizure freedom. In these reports, symptoms 
occurred mostly within the ﬁ  rst month of therapy, but they 
could develop at any time during treatment. Dose reduction 
or discontinuation has led to resolution of symptoms in the 
cases reported. Overall, these studies illustrated that a close 
clinical monitoring with regard to psychiatric adverse events 
is related to the psychiatric proﬁ  le of the patient (Kossoff 
et al 2001; Mula et al 2003). Conversely, LEV has no major 
adverse effects on cognitive function (Neyens et al 1995).
Clinical antiepileptic effect
Add on therapy in partial epilepsy
The efﬁ  cacy of LEV as add on therapy has been assessed 
in 5 prospective, double blind, placebo controlled trials in Neuropsychiatric Disease and Treatment 2008:4(1) 36
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patients with uncontrolled partial seizures (Ben-Menachem 
and Falter 2000; Cereghino et al 2000; Shorvon et al 2000; 
Glauser et al 2006; Tsai et al 2006). Four of these studies 
enrolled adult patients with at least 2 refractory partial 
seizures per 4 weeks (Ben-Menachem and Falter 2000; 
Cereghino et al 2000; Shorvon et al 2000; Tsai et al 2006). 
The ﬁ  fth study was carried out in children aged 4–16 years 
(Glauser et al 2006). Doses of LEV evaluated in adults 
included 1000, 2000, and 3000 mg/day given in twice-daily 
regimens. Dose titration was of 4 weeks, followed by 12–14 
weeks of maintenance. At all dosages evaluated in these 
three studies, LEV was signiﬁ  cantly more effective than 
placebo. The median percentage reduction from baseline 
was 32.5% for patients receiving LEV compared with 7% for 
those receiving placebo (p   0.001). During the evaluation 
period, the responder rate, that is the proportion of patients 
experiencing a 50% or greater reduction in seizure frequency 
compared with baseline, was 27.7% (54/195), 31.6% (30/95), 
and 41.3% (111/269) for patients receiving 1000, 2000, and 
3000 mg/day respectively, compared with 12.6% (38/301) of 
patients who received placebo (p   0.001, all doses versus 
placebo). The percentage of patients experiencing a 75% or 
greater reduction in seizures was 11.8% (23/195), 16.8% 
(16/95), and 22.3% (60/269) of patients receiving 1000 mg, 
2000 mg, and 3000 mg of LEV respectively, compared with 
3.3% (10/301) of placebo treated patients (p   0.001, all doses 
versus placebo). In addition, 5.7% (32/559) of patients treated 
with LEV became seizure free, compared with 0.6% (2/301)
in the placebo group (p   0.001) (Cereghino et al 2000).
A statistically signiﬁ  cant reduction in seizure frequency 
for all different subtypes of partial seizures (simple partial, 
complex partial, and secondarily generalized seizures) was 
found with LEV treatment. In addition a pooled analysis 
derived from the three studies in adults demonstrates a 
speciﬁ  c independent reduction of secondary generalized 
seizures (median percentage reduction: 68.5%) (Leppik 
et al 2003).
A large multicenter, randomized, placebo-controlled trial 
illustrated that LEV as adjunctive therapy administered at 60 
mg/kg/day is also efﬁ  cacious and well tolerated in children 
with drug-resistant partial seizures (Glauser et al 2006). 
During the treatment period, 198 patients received either 
placebo or LEV add-on therapy and were up-titrated to a 
target dose of 60 mg/kg/day. There was a signiﬁ  cant (26.8%; 
p   0.0002; 95% CI 14.0%–37.6%) reduction in partial onset 
seizure frequency per week for LEV adjunctive therapy over 
placebo adjunctive therapy. A 50% or greater reduction of 
partial seizure frequency per week was attained in 44.6% 
of the LEV group (45/101 patients), compared with 19.6% 
(19/97 patients) receiving placebo (p = 0.0002).
Monotherapy
Although LEV is well tolerated with a favorable pharmacoki-
netic proﬁ  le, few works demonstrated successful conversion 
to monotherapy in patients with refractory epilepsy, and few 
studies with small number of patients demonstrate its effec-
tiveness as a single agent in partial epilepsy (Ben-Menachem 
and Falter 2000; Alsaadi et al 2005; Brodie et al 2007). In 
a multicenter double-blind, responder selected study (Ben-
Menachem and Falter 2000), it was evaluated the efﬁ  cacy 
and tolerability of LEV monotherapy in selected patients with 
refractory focal epilepsy: in the LEV monotherapy group 
the median percent reduction in partial seizure frequency 
compared with baseline was 73.8% with a responder rate 
of 59.2%.
In an open study, LEV was efﬁ  cacious as monotherapy 
in 46 patients with newly diagnosed naïve epilepsy or with 
chronic difﬁ  cult to control epilepsy who were followed for 
1 year (Alsaadi et al 2005). In this study, the majority (82%) 
of the patients remained on LEV for at least 1 year with more 
than 50% of patients remaining seizure free. Moreover, a 
recent randomized double-blind trial involving 579 patients 
comparing LEV with controlled-release carbamazepine 
illustrated that both AEDs have produced equivalent seizure 
freedom rates in newly diagnosed epilepsy at optimal dosing 
in a setting mimicking clinical practice (Brodie et al 2007). 
Importantly, no other newer AED has been shown to be 
equivalent to an older generation AED (Brodie et al 2007). 
Furthermore, long-term evaluation of the patients enrolled 
in these trials, as well as several others, suggests that LEV is 
both efﬁ  cacious and well tolerated by most patients. Based 
on compiled results, retention rates are estimated to be 60% 
at 1 year and 32% at 5 years (Krakow et al 2001).
IV therapy
LEV IV infusion is bioequivalent to oral tablets and is well 
tolerated after 15-min (2000–4000) and 5-min (1500–2500) 
IV infusions in healthy subjects (Ramael et al 2006a, b). 
Among the newer agents LEV has been the first to be 
approved for IV application. The results of a small, mul-
ticenter, open-label study (Baulac et al 2007) suggest that 
a 15-min infusion (500–1500 mg, bid) is well tolerated in 
patients with partial onset seizures when administered over a 
4-day period. The observed adverse events were mild to mod-
erate and the most frequently reported ones were headache 
and fatigue. None of the subjects discontinued because of Neuropsychiatric Disease and Treatment 2008:4(1) 37
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adverse events and no serious adverse events were reported. 
These results support dosing ﬂ  exibility and easy conversion 
from oral to IV LEV, and back, in patients with partial-onset 
seizures temporarily unable to take the drug orally.
Conclusions
LEV is a novel antiepileptic drug which has been approved 
as adjunctive treatment for adults with partial onset 
seizures. Its effectiveness was established in ﬁ  ve multi-
center, well-controlled pivotal trials. In addition, LEV is 
well tolerated with a favorable pharmacokinetic proﬁ  le 
that includes minimal protein binding, lack of hepatic 
metabolism, and twice a day dosing. These features and 
others make it ideal for use as monotherapy (French et al 
2004a, b). The majority of studies on LEV monotherapy 
effect in focal epilepsies in children, in adults, and in the 
elderly are based on retrospective evaluation of small series 
of patients with a short-term follow up; only one study 
compares LEV to an traditional AED; more additional 
randomized double-blind monotherapy trials are needed 
to conﬁ  rm these ﬁ  ndings.
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